New drug LW402 takes first step: safety check in 36 volunteers
NCT ID NCT07546149
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety and tolerability of LW402 tablets in 36 healthy volunteers. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moves through the body. Since this is a Phase 1 study, the main goal is to see if the drug is safe enough to test in larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LW402 tablets
- What this could lead to
- If successful, this could pave the way for future studies of LW402 as a potential treatment for an unspecified condition.
- What could go wrong
- This is a very early Phase 1 trial with only 36 healthy volunteers, so it cannot prove the drug works for any disease. Side effects or lack of tolerability may stop further development.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY EVALUATION OF ESCALATING DOSES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.